Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRE | P78334 | 1/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31718018 | 1.00 | APP (0.52) | APPGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL18429675 | 0.89 | APP (0.55) | APP | |
| SCHEMBL1187575 | 0.80 | APP (0.65) | APP | |
| SCHEMBL198499 | 0.79 | CYP1A2 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30454012 | 0.79 | CYP1A2 (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL510168 | 0.78 | GABRA5 (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16964639 | 0.78 | GABRG2 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL224083 | 0.78 | MAOB (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12203827 | 0.78 | PKM (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4288596 | 0.78 | PLAU (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128873-A1 | HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240140933-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4341252-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. Hoffmann-La Roche AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| CN-117321042-A | Oxodihydro indole compounds for the treatment of inflammatory diseases or cancers | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230002679-A1 | COMPOUND AND LIQUID CRYSTAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2023-01-05 | — | — | US | disclosed |
| WO-2022243346-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-24 | — | — | WO | disclosed |
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | MODERNATX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-2699558-B1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| EP-0948511-B1 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-6248878-B1 | INCLUDING BASES 2-FLUOROPYRIDINE-3-YL, PYRIDINE-2-ONE-3-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-3-YL, 2-BROMOPYRIDINE-5-YL , PYRIDIN-2-ONE-5-YL, 2-AMINOPYRIDINE-5-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-5-YL; ANTISENSE/ANTICANCER AGENTS | RIBOZYME PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | disclosed |
| EP-0948511-A2 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998028317-A2 | SYNTHESIS OF NUCLEOSIDES AND POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | APP 4405/4885GABRP 4527/4885GABRD 4608/4885 |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | APP 4405/4885GABRP 4527/4885GABRD 4608/4885 |
| US-20240140933-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | IL1B, IL1A, IL1R1 | APP 2653/4885GABRP 4661/4885GABRD 4711/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | APP 4405/4885GABRP 4527/4885GABRD 4608/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | APP 4405/4885GABRP 4527/4885GABRD 4608/4885 |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | NSUN2, RNGTT, NSUN3 | APP 4405/4885GABRP 4527/4885GABRD 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.